Investing.com - Financial Markets Worldwide

Lepu Biopharma Co Ltd (2157)

Hong Kong
Currency in HKD
8.55
-0.54(-5.94%)
Delayed Data·
2157 Scorecard
Full Analysis
Impressive gross profit margins
2157 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
8.439.10
52 wk Range
2.2610.50
Key Statistics
Edit
Bid/Ask
8.55 / 8.57
Prev. Close
9.09
Open
9.09
Day's Range
8.43-9.1
52 wk Range
2.26-10.5
Volume
11.35M
Average Volume (3m)
34.73M
1-Year Change
282.52%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2157 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 15
Analysts anticipate sales decline in the current year
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Lepu Biopharma Co Ltd Company Profile

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of first-in class and best-in-class drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive. In addition, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin’s lymphoma; CMG901 CLDN18.2-targeted ADC for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC for treating advanced or metastatic solid tumors. Further, it is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG006A and CTM012 for the treatment of solid tumors. The company was incorporated in 2018 and is headquartered in Shanghai, China.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
546
Market
Hong Kong

Compare 2157 to Peers and Sector

Metrics to compare
2157
Peers
Sector
Relationship
P/E Ratio
0.0x−20.3x−0.6x
PEG Ratio
0.000.220.00
Price/Book
0.0x6.0x2.6x
Price / LTM Sales
0.0x21.5x3.3x
Upside (Analyst Target)
0.0%−9.5%38.7%
Fair Value Upside
Unlock−9.5%5.1%Unlock

Earnings

Latest Release
Aug 20, 2025
EPS / Forecast
0.02 / --
Revenue / Forecast
465.94M / --
EPS Revisions
a
a
Unlock
Last 90 days

2157 Income Statement

FAQ

What Stock Exchange Does Lepu Biopharma Trade On?

Lepu Biopharma is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Lepu Biopharma?

The stock symbol for Lepu Biopharma is "2157."

What Is the Lepu Biopharma Market Cap?

As of today, Lepu Biopharma market cap is 12.78B.

What Is Lepu Biopharma's Earnings Per Share (TTM)?

The Lepu Biopharma EPS (TTM) is -0.10.

From a Technical Analysis Perspective, Is 2157 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Lepu Biopharma Stock Split?

Lepu Biopharma has split 0 times.

How Many Employees Does Lepu Biopharma Have?

Lepu Biopharma has 546 employees.

What is the current trading status of Lepu Biopharma (2157)?

As of 28 Aug 2025, Lepu Biopharma (2157) is trading at a price of 8.55, with a previous close of 9.09. The stock has fluctuated within a day range of 8.43 to 9.10, while its 52-week range spans from 2.26 to 10.50.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.